GGrantIndex
← Leaderboards

Fred Valentine

New York University School Of Medicine

Google Scholar ↗PubMed ↗ORCID ↗
$14,208,248
Attributed
$14,208,248
Total exposure
71
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $5.8M · FY2005–10
$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10

Funding mix

By agency

NIH$42,551,428 · 73

By mechanism

P30$20,251,247 · 5
P01$11,665,422 · 3
U01$6,789,922 · 1
M01$3,183,720 · 63
R01$661,117 · 1

Top collaborators

No co-investigators on record.

Most similar at New York University School Of Medicine

Same institution · by research overlap

Others in their field

Top investigators on “Clinical Research”

Research focus

Clinical ResearchHuman SubjectAids TherapyHuman Therapy EvaluationHiv InfectionsAntiaids AgentCombination ChemotherapyDrug Screening /EvaluationPatient Oriented ResearchIndinavirProtease InhibitorClinical TrialsZidovudineLamivudineVirus RnaClinical Trial Phase IPharmacokineticsNucleoside AnalogReverse Transcriptase InhibitorsAidsHuman Immunodeficiency VirusDrug Adverse EffectHuman Immunodeficiency Virus 1Helper T Lymphocyte

Grant awards (182)

Center for AIDS Research$916,876
P30 · FY2010 · AI · contact PI
Administrative$227,614
P30 · FY2010 · AI · contact PI
Center for AIDS Research$1,977,464
P30 · FY2009 · AI · contact PI
Immunopathogenesis of acute and early HIV infection$436,997
P01 · FY2009 · AI · contact PI
Immunopathogenesis of acute and early HIV infection$2,106,243
P01 · FY2008 · AI · contact PI
Center for AIDS Research$2,080,346
P30 · FY2008 · AI · contact PI
CD4 RESPONSES TO ANTIRETROVIRAL THERAPY (ART) ALONE OR ART WITH VACCINATION$956,222
M01 · FY2008 · RR · contact PI
Immune responses to acute HIV infection$352,386
P01 · FY2008 · AI · contact PI
Immunological control of HIV in vivo$336,490
P01 · FY2008 · AI · contact PI
Immunopathogenesis of acute and early HIV infection$1,836,106
P01 · FY2007 · AI · contact PI
Center for AIDS Research$1,438,777
P30 · FY2007 · AI · contact PI
CD4 RESPONSES TO ANTIRETROVIRAL THERAPY (ART) ALONE OR ART WITH VACCINATION$412,652
M01 · FY2007 · RR · contact PI
Immune responses to acute HIV infection$283,780
P01 · FY2007 · AI · contact PI
Immunological control of HIV in vivo$282,527
P01 · FY2007 · AI · contact PI
Center for AIDS Research$1,875,520
P30 · FY2006 · AI · contact PI
Immunopathogenesis of acute and early HIV infection$1,830,410
P01 · FY2006 · AI · contact PI
Immune responses to acute HIV infection$289,710
P01 · FY2006 · AI · contact PI
Immunological control of HIV in vivo$288,425
P01 · FY2006 · AI · contact PI
CD4 RESPONSES TO ANTIRETROVIRAL THERAPY (ART) ALONE OR ART WITH VACCINATION$117,016
M01 · FY2006 · RR · contact PI
Center for AIDS Research$2,596,614
P30 · FY2005 · AI
Immunopathogenesis of acute and early HIV infection$1,817,648
P01 · FY2005 · AI
OAR Supplement$359,102
P30 · FY2005 · AI
ADMINISTRATIVE CORE$306,980
P30 · FY2005 · AI
Immune responses to acute HIV infection$280,928
P01 · FY2005 · AI
Immunological control of HIV in vivo$279,685
P01 · FY2005 · AI
ACTG A5082: METFORMIN &ROSIGLITAZONE IN HIV+ PTS W/ INSULIN &FAT ABNORMALITIES$7,732
M01 · FY2005 · RR
ACTG A5150: VIROLOGIC &IMMUNOLOGIC CHANGES IN WOMEN WITH HIV DURING POSTPARTUM$2,579
M01 · FY2005 · RR
ACTG A5116: PROTEASE INHIBITOR SPARING REGIMENS V NUCLEOSIDE-SPARING REGIMENS$2,577
M01 · FY2005 · RR
ACTG 5084: METABOLIC COMPLICATIONS IN HIV-1-INFECTED PREGNANT WOMEN ON ART$1,287
M01 · FY2005 · RR
CENTER FOR AIDS RESEARCH$1,625,620
P30 · FY2004 · AI
Immunopathogenesis of acute and early HIV infection$958,225
P01 · FY2004 · AI
HIV pathogenesis and responoses to therapy in Africans$339,623
P30 · FY2004 · AI
ACTG 371: 3TC/ZDV/ABC/APV in Acute HIV Infection or Seroconversion$281,831
M01 · FY2004 · RR
ACTG A5073:Twice Daily -v- Once Daily HAARTand Self-Administered versus DOT$170,998
M01 · FY2004 · RR
ACTG A5095: 3 Protease Inhibitor-Sparing Regimens for Initial Treatment of HIV$144,082
M01 · FY2004 · RR
Immune responses to acute HIV infection$143,248
P01 · FY2004 · AI
Immunological control of HIV in vivo$142,614
P01 · FY2004 · AI
ACTG A5068: Withdrawal of Antiretrovirals + HIV Vaccine$135,373
M01 · FY2004 · RR
Adult AIDS Clinical Trial Group Longitudinal Linked Randomized Trials Protocol$111,624
M01 · FY2004 · RR
Effect of Thymidine Analogue Change to Nucleoside-Sparing Regimen on Fat Wasting$51,458
M01 · FY2004 · RR
ACTG A5146: THERAPEUTIC DRUG MONITORING IN SUBJECTS WITH A LOW NIQ TO PIS$50,665
M01 · FY2004 · RR
ACTG A5142: COMPARISON OF THREE ANTIVIRAL REGIMENS FOR INITIAL THERAPY OF HIV-1$43,540
M01 · FY2004 · RR
ACTG A5170: PREDICTORS OF DISEASE PROGRESSION IN SUBJECTS WHO DISCONTINUE ART$34,040
M01 · FY2004 · RR
ACTG A5116: Protease Inhibitor Sparing Regimens v. Nucleoside-Sparing Regimens$19,791
M01 · FY2004 · RR
Predictive Value of PK-Adjusted Phenotypic Susceptibility on Antiretroviral Resp$18,209
M01 · FY2004 · RR
ACTG A5127: TREATMENT OF LAMIVUDINE-RESISTANT HBV/HIV CO-INFECTED SUBJECTS$14,250
M01 · FY2004 · RR
ACTG A5172: USING HELPER AND CTL RESPONSES TO CONTROL V$14,250
M01 · FY2004 · RR
ACTG A5164:IMMEDIATE VS DELAYED ART FOR HIV-INFECTED PATIENTS WITH ACUTE OT$13,459
M01 · FY2004 · RR
ACTG A5143: Lopinavir (LPV)/Ritonavir (RTV) vs GW433908/RTV vs LPV/RTV/GW433908$12,666
M01 · FY2004 · RR
ACTG A5092s: Pharmacokinetic Effects of RBV on ZDV or d4T Triphosphate Formation$12,666
M01 · FY2004 · RR
ACTG A5163: ALENDRONATE IN HIV SUBJECTS WITH DECREASED$11,875
M01 · FY2004 · RR
ACTG A5079: TESTOSTERONE SUPPLEMENTATION FOR HIV-POSITIVE MEN$10,291
M01 · FY2004 · RR
TEMPORARY CESSATION OF ANTIRETROVIRAL TREATMENT IN PATIENTS FAILING THERAPY$10,291
M01 · FY2004 · RR
ACTG A5082: Metformin &Rosiglitazone in HIV+ Pts w/ Insulin &Fat Abnormalities$9,500
M01 · FY2004 · RR
ACTG 362: Azithromycin Prophylaxis for Primary Prevention of MAC in AIDS$7,916
M01 · FY2004 · RR
ACTG 372: Indinavir + Nucleoside Analogs: Virologic Success and Failure$7,125
M01 · FY2004 · RR
AUGMENTATION OF IMMUNE RESPONSE THROUGH VACCINATION IN INDIVIDUALS ON HAART$6,334
M01 · FY2004 · RR
ACTG 736: CSF HIV-1 &Cognitive Function in Patients on Potent HAART$5,541
M01 · FY2004 · RR
ACTG A5029: HUMAN PAPILLOMA VIRUS IN ANTIRETROVIRAL NAIVE HIV+ WOMEN ON HAART$4,750
M01 · FY2004 · RR
ACTG A5128: OBTAINING INFORMED CONSENT TO USE STORED HUMAN BIOLOGICAL MATERIALS$3,959
M01 · FY2004 · RR
ACTG A5030: Valganciclovir for Pre-Emptive Therapy for Cytomegalovirus$3,166
M01 · FY2004 · RR
ACTG A5135: FIXED- VS ADJUSTED-DOSE LOPINAVIR/RITONAVIR$3,166
M01 · FY2004 · RR
ACTG A5115: ANTIRETROVIRAL SWITCH AT LOWER VERSUS HIGHER HIV-1 RNA LEVELS$3,166
M01 · FY2004 · RR
ACTG A5173:CLEARANCE OF HIV-1 IN CD4+ CELLS OF SUBJECTS ON T-20 PLUS ORAL AR$2,375
M01 · FY2004 · RR
ACTG 5084: Metabolic Complications in HIV-1-Infected Pregnant Women on ART$1,584
M01 · FY2004 · RR
ACTG A5103:Protease Inhibitor-Sparing Regimens to Improve Metabolic Abnormalitie$791
M01 · FY2004 · RR
ACTG A5150: VIROLOGIC &IMMUNOLOGIC CHANGES IN WOMEN WI$791
M01 · FY2004 · RR
ADULT AIDS CLINICAL TRIALS UNIT$1,667,113
U01 · FY2003 · AI
CENTER FOR AIDS RESEARCH$1,578,271
P30 · FY2003 · AI
CENTER FOR AIDS RESEARCH$1,858,147
P30 · FY2002 · AI
ADULT AIDS CLINICAL TRIALS UNIT$1,655,127
U01 · FY2002 · AI
ACTG 307--HYDROXYUREA +/- DDI COMPARED WITH DDI ALONE IN HIV INFECTED PATIENTS$0
M01 · FY2002 · RR
LYMPHOKINES ON METASTATIC MALIGNANT MELANOMA$0
M01 · FY2002 · RR
IL-2 PLUS ANTIRETROVIRAL THERAPY VERSUS ANTIRETROVIRAL ALONE IN HIV+ PATIENTS$0
M01 · FY2002 · RR
ACTG 320--INDINAVIR W/ ZDV OR D4T &3TC IN PTS W/ CD4<200 &>3 MON PRIOR ZDV$0
M01 · FY2002 · RR
141W94/VX-478 PLUS ZDV PLUS 3TC IN HIV-INFECTED INDIVIDUALS$0
M01 · FY2002 · RR
INDINAVIR, DMP-266 AND 1592U89 IN HIV-INFECTED SUBJECTS$0
M01 · FY2002 · RR
THREE REGIMENS FOR HIV-INFECTED SUBJECTS ON ZDV, LAMIVUIDINE AND INDINAVIR$0
M01 · FY2002 · RR
ZDV/3TC/NEVIRAPINE AND ZDV/3TC/NEVIRAPINE/1592U89 IN HIV-INFECTED CHILDREN$0
M01 · FY2002 · RR
FLUCONAZOLE IN HIV+ SUBJECTS WITH RECURRENT OROPHARYNGEA CANDIDIASIS$0
M01 · FY2002 · RR
RHIL2 IN HIV+ SUBJECTS ON HAART COMPARED TO HAART ALONE$0
M01 · FY2002 · RR
ORAL ISOTRETINOIN VERSUS OBSERVATION FOR LOW GRADE CERVICAL DYSPLASIA$0
M01 · FY2002 · RR
NELFINAVIR AND/OR DMP-266 PLUS NUCLEOSIDE ANALOGS IN NUCLEOSIDE EXPERIENCE$0
M01 · FY2002 · RR
ACTIVITY OF SOFT GEL CAPSULE OF SAQUINAVIR IN ANTIRETROVIRAL REGIMENS$0
M01 · FY2002 · RR
INDINAVIR PLUS NUCLEOSIDE ANALOGS--VIROLOGIC SUCCESS AND FAILURE$0
M01 · FY2002 · RR
141W94/VX-478+3TC+ZDV OR NEVIRAPINE+3TC+STAVUDINE$0
M01 · FY2002 · RR
ACTG 334:CYCLOSPORIN IN IMMUNE ACTIVATION &HIV EXPRESSION IN EARLY HIV$0
M01 · FY2002 · RR
ACTG 365:STEADY STATE PHARMACOKINETIC INTERACTION STUDY OF INDINAVIR$0
M01 · FY2002 · RR
ACTG 362: AZITHROMYCIN PROPHYLAXIS FOR PRIMARY PREVENTION OF MAC IN AIDS$0
M01 · FY2002 · RR
ACTG 363: CIDOFOVIR FOR PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY IN AIDS$0
M01 · FY2002 · RR
ACTG 388: EFZ + NFV W/ 3TC/ZDV &IDV IN HIV+ PTS W/ CD4 <200 &>100,$0
M01 · FY2002 · RR
ACTG 398: AMPRENAVIR + ABACAVIR, EFAVIRENZ &ADEFOVIR IN HIV+ PTS$0
M01 · FY2002 · RR
TRI 003: T 20 ADMINISTERED TO HIV+ ADULTS BY SQ INFUSION V SQ INJECTION$0
M01 · FY2002 · RR
ACTG 384: PI +/ NNRTI W/ DUAL NUCLEOSIDES FOR INITIAL RX OF HIV INFECTION$0
M01 · FY2002 · RR
ADULT AIDS CLINICAL TRIALS UNIT$1,705,127
U01 · FY2001 · AI
CENTER FOR AIDS RESEARCH$1,487,673
P30 · FY2001 · AI
CRYPTIC EPITOPES--IMMUNIZATION BY MULTIPLE CHAIN PEPTIDE$335,049
R01 · FY2001 · AI
CENTER FOR AIDS RESEARCH$110,532
P30 · FY2001 · AI
ACTG 334:CYCLOSPORIN IN IMMUNE ACTIVATION &HIV EXPRESSION IN EARLY HIV$0
M01 · FY2001 · RR
141W94/VX-478+3TC+ZDV OR NEVIRAPINE+3TC+STAVUDINE$0
M01 · FY2001 · RR
INDINAVIR PLUS NUCLEOSIDE ANALOGS--VIROLOGIC SUCCESS AND FAILURE$0
M01 · FY2001 · RR
ACTIVITY OF SOFT GEL CAPSULE OF SAQUINAVIR IN ANTIRETROVIRAL REGIMENS$0
M01 · FY2001 · RR
ACTG 384: PI +/ NNRTI W/ DUAL NUCLEOSIDES FOR INITIAL RX OF HIV INFECTION$0
M01 · FY2001 · RR
TRI 003: T 20 ADMINISTERED TO HIV+ ADULTS BY SQ INFUSION V SQ INJECTION$0
M01 · FY2001 · RR
CORE--FLOW CYTOMETRY FACILITY$0
P30 · FY2001 · AI
ACTG 398: AMPRENAVIR + ABACAVIR, EFAVIRENZ &ADEFOVIR IN HIV+ PTS$0
M01 · FY2001 · RR
ACTG 388: EFZ + NFV W/ 3TC/ZDV &IDV IN HIV+ PTS W/ CD4 <200 &>100,$0
M01 · FY2001 · RR
NELFINAVIR AND/OR DMP-266 PLUS NUCLEOSIDE ANALOGS IN NUCLEOSIDE EXPERIENCE$0
M01 · FY2001 · RR
ORAL ISOTRETINOIN VERSUS OBSERVATION FOR LOW GRADE CERVICAL DYSPLASIA$0
M01 · FY2001 · RR
RHIL2 IN HIV+ SUBJECTS ON HAART COMPARED TO HAART ALONE$0
M01 · FY2001 · RR
FLUCONAZOLE IN HIV+ SUBJECTS WITH RECURRENT OROPHARYNGEA CANDIDIASIS$0
M01 · FY2001 · RR
ZDV/3TC/NEVIRAPINE AND ZDV/3TC/NEVIRAPINE/1592U89 IN HIV-INFECTED CHILDREN$0
M01 · FY2001 · RR
THREE REGIMENS FOR HIV-INFECTED SUBJECTS ON ZDV, LAMIVUIDINE AND INDINAVIR$0
M01 · FY2001 · RR
INDINAVIR, DMP-266 AND 1592U89 IN HIV-INFECTED SUBJECTS$0
M01 · FY2001 · RR
141W94/VX-478 PLUS ZDV PLUS 3TC IN HIV-INFECTED INDIVIDUALS$0
M01 · FY2001 · RR
ACTG 307--HYDROXYUREA +/- DDI COMPARED WITH DDI ALONE IN HIV INFECTED PATIENTS$0
M01 · FY2001 · RR
ACTG 320--INDINAVIR W/ ZDV OR D4T &3TC IN PTS W/ CD4<200 &>3 MON PRIOR ZDV$0
M01 · FY2001 · RR
IL-2 PLUS ANTIRETROVIRAL THERAPY VERSUS ANTIRETROVIRAL ALONE IN HIV+ PATIENTS$0
M01 · FY2001 · RR
LYMPHOKINES ON METASTATIC MALIGNANT MELANOMA$0
M01 · FY2001 · RR
ACTG 363: CIDOFOVIR FOR PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY IN AIDS$0
M01 · FY2001 · RR
ACTG 362: AZITHROMYCIN PROPHYLAXIS FOR PRIMARY PREVENTION OF MAC IN AIDS$0
M01 · FY2001 · RR
ACTG 365:STEADY STATE PHARMACOKINETIC INTERACTION STUDY OF INDINAVIR$0
M01 · FY2001 · RR
ADULT AIDS CLINICAL TRIALS UNIT$1,762,555
U01 · FY2000 · AI
CENTER FOR AIDS RESEARCH$1,472,088
P30 · FY2000 · AI
CRYPTIC EPITOPES--IMMUNIZATION BY MULTIPLE CHAIN PEPTIDE$326,068
R01 · FY2000 · AI
RHIL2 IN HIV+ SUBJECTS ON HAART COMPARED TO HAART ALONE$21,006
M01 · FY2000 · RR
FLUCONAZOLE IN HIV+ SUBJECTS WITH RECURRENT OROPHARYNGEA CANDIDIASIS$21,006
M01 · FY2000 · RR
ZDV/3TC/NEVIRAPINE AND ZDV/3TC/NEVIRAPINE/1592U89 IN HIV-INFECTED CHILDREN$21,006
M01 · FY2000 · RR
THREE REGIMENS FOR HIV-INFECTED SUBJECTS ON ZDV, LAMIVUIDINE AND INDINAVIR$21,006
M01 · FY2000 · RR
141W94/VX-478 PLUS ZDV PLUS 3TC IN HIV-INFECTED INDIVIDUALS$21,006
M01 · FY2000 · RR
ACTG 307--HYDROXYUREA +/- DDI COMPARED WITH DDI ALONE IN HIV INFECTED PATIENTS$21,006
M01 · FY2000 · RR
ACTG 320--INDINAVIR W/ ZDV OR D4T &3TC IN PTS W/ CD4<200 &>3 MON PRIOR ZDV$21,006
M01 · FY2000 · RR
IL-2 PLUS ANTIRETROVIRAL THERAPY VERSUS ANTIRETROVIRAL ALONE IN HIV+ PATIENTS$21,006
M01 · FY2000 · RR
ACTG 384: PI +/ NNRTI W/ DUAL NUCLEOSIDES FOR INITIAL RX OF HIV INFECTION$21,006
M01 · FY2000 · RR
TRI 003: T 20 ADMINISTERED TO HIV+ ADULTS BY SQ INFUSION V SQ INJECTION$21,006
M01 · FY2000 · RR
ACTG 398: AMPRENAVIR + ABACAVIR, EFAVIRENZ &ADEFOVIR IN HIV+ PTS$21,006
M01 · FY2000 · RR
ACTG 388: EFZ + NFV W/ 3TC/ZDV &IDV IN HIV+ PTS W/ CD4 <200 &>100,$21,006
M01 · FY2000 · RR
ACTG 363: CIDOFOVIR FOR PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY IN AIDS$21,006
M01 · FY2000 · RR
ACTG 362: AZITHROMYCIN PROPHYLAXIS FOR PRIMARY PREVENTION OF MAC IN AIDS$21,006
M01 · FY2000 · RR
ACTG 365:STEADY STATE PHARMACOKINETIC INTERACTION STUDY OF INDINAVIR$21,006
M01 · FY2000 · RR
ACTG 334:CYCLOSPORIN IN IMMUNE ACTIVATION &HIV EXPRESSION IN EARLY HIV$21,006
M01 · FY2000 · RR
141W94/VX-478+3TC+ZDV OR NEVIRAPINE+3TC+STAVUDINE$21,006
M01 · FY2000 · RR
INDINAVIR PLUS NUCLEOSIDE ANALOGS--VIROLOGIC SUCCESS AND FAILURE$21,006
M01 · FY2000 · RR
ACTIVITY OF SOFT GEL CAPSULE OF SAQUINAVIR IN ANTIRETROVIRAL REGIMENS$21,006
M01 · FY2000 · RR
NELFINAVIR AND/OR DMP-266 PLUS NUCLEOSIDE ANALOGS IN NUCLEOSIDE EXPERIENCE$21,006
M01 · FY2000 · RR
LYMPHOKINES ON METASTATIC MALIGNANT MELANOMA$21,006
M01 · FY2000 · RR
ORAL ISOTRETINOIN VERSUS OBSERVATION FOR LOW GRADE CERVICAL DYSPLASIA$21,006
M01 · FY2000 · RR
INDINAVIR, DMP-266 AND 1592U89 IN HIV-INFECTED SUBJECTS$0
M01 · FY2000 · RR
ACTG 362: AZITHROMYCIN PROPHYLAXIS FOR PRIMARY PREVENTION OF MAC IN AIDS$0
M01 · FY2000 · RR
THREE REGIMENS FOR HIV-INFECTED SUBJECTS ON ZDV, LAMIVUIDINE AND INDINAVIR$0
M01 · FY2000 · RR
ZDV/3TC/NEVIRAPINE AND ZDV/3TC/NEVIRAPINE/1592U89 IN HIV-INFECTED CHILDREN$0
M01 · FY2000 · RR
ACTG 365:STEADY STATE PHARMACOKINETIC INTERACTION STUDY OF INDINAVIR$0
M01 · FY2000 · RR
ACTG 334:CYCLOSPORIN IN IMMUNE ACTIVATION &HIV EXPRESSION IN EARLY HIV$0
M01 · FY2000 · RR
FLUCONAZOLE IN HIV+ SUBJECTS WITH RECURRENT OROPHARYNGEA CANDIDIASIS$0
M01 · FY2000 · RR
NELFINAVIR AND/OR DMP-266 PLUS NUCLEOSIDE ANALOGS IN NUCLEOSIDE EXPERIENCE$0
M01 · FY2000 · RR
141W94/VX-478+3TC+ZDV OR NEVIRAPINE+3TC+STAVUDINE$0
M01 · FY2000 · RR
INDINAVIR PLUS NUCLEOSIDE ANALOGS--VIROLOGIC SUCCESS AND FAILURE$0
M01 · FY2000 · RR
RHIL2 IN HIV+ SUBJECTS ON HAART COMPARED TO HAART ALONE$0
M01 · FY2000 · RR
ACTIVITY OF SOFT GEL CAPSULE OF SAQUINAVIR IN ANTIRETROVIRAL REGIMENS$0
M01 · FY2000 · RR
ORAL ISOTRETINOIN VERSUS OBSERVATION FOR LOW GRADE CERVICAL DYSPLASIA$0
M01 · FY2000 · RR
DISCONTINUING THERAPY IN DISSEMINATED MYCOBACTERIUM AVIU$0
M01 · FY2000 · RR
HEPATITIS C DYNAMICS WITH HIV AND AIDS THERAPY$0
M01 · FY2000 · RR
HEPATITIS C DYNAMICS WITH HIV AND AIDS THERAPY$0
M01 · FY2000 · RR
HIV RNA SUPPRESSION WITH DDI/4TD/HU VS DDI/D4T/EFV$0
M01 · FY2000 · RR
HIV RNA SUPPRESSION WITH DDI/4TD/HU VS DDI/D4T/EFV$0
M01 · FY2000 · RR
LAMIVUDINE, ZIDOVUDINE, ABACAVIR, PLUS AMPRENAVIR IN HIV$0
M01 · FY2000 · RR
LAMIVUDINE, ZIDOVUDINE, ABACAVIR, PLUS AMPRENAVIR IN HIV$0
M01 · FY2000 · RR
LYMPHOKINES ON METASTATIC MALIGNANT MELANOMA$0
M01 · FY2000 · RR
DISCONTINUING THERAPY IN DISSEMINATED MYCOBACTERIUM AVIU$0
M01 · FY2000 · RR
DISCONTINUING PCP PROPHYLAXIS IN AIDS THERAPY--CD4>200$0
M01 · FY2000 · RR
DISCONTINUING PCP PROPHYLAXIS IN AIDS THERAPY--CD4>200$0
M01 · FY2000 · RR
RHIL 12 FOR CD4 LESS THAN 50 AND BETWEEN 300-500$0
M01 · FY2000 · RR
RHIL 12 FOR CD4 LESS THAN 50 AND BETWEEN 300-500$0
M01 · FY2000 · RR
IL-2 PLUS ANTIRETROVIRAL THERAPY VERSUS ANTIRETROVIRAL ALONE IN HIV+ PATIENTS$0
M01 · FY2000 · RR
ACTG 384: PI +/ NNRTI W/ DUAL NUCLEOSIDES FOR INITIAL RX OF HIV INFECTION$0
M01 · FY2000 · RR
TRI 003: T 20 ADMINISTERED TO HIV+ ADULTS BY SQ INFUSION V SQ INJECTION$0
M01 · FY2000 · RR
ACTG 320--INDINAVIR W/ ZDV OR D4T &3TC IN PTS W/ CD4<200 &>3 MON PRIOR ZDV$0
M01 · FY2000 · RR
ACTG 398: AMPRENAVIR + ABACAVIR, EFAVIRENZ &ADEFOVIR IN HIV+ PTS$0
M01 · FY2000 · RR
ACTG 307--HYDROXYUREA +/- DDI COMPARED WITH DDI ALONE IN HIV INFECTED PATIENTS$0
M01 · FY2000 · RR
ACTG 388: EFZ + NFV W/ 3TC/ZDV &IDV IN HIV+ PTS W/ CD4 <200 &>100,$0
M01 · FY2000 · RR
141W94/VX-478 PLUS ZDV PLUS 3TC IN HIV-INFECTED INDIVIDUALS$0
M01 · FY2000 · RR
ACTG 363: CIDOFOVIR FOR PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY IN AIDS$0
M01 · FY2000 · RR